Switch theme
Sign up to access all valuation multiples
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
2016
183
LTM Revenue $143M
Last FY EBITDA $50.8M
-$37.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Entrada Therapeutics has a last 12-month revenue (LTM) of $143M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Entrada Therapeutics achieved revenue of $211M and an EBITDA of $50.8M.
Entrada Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Entrada Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $143M | XXX | $211M | XXX | XXX | XXX |
| Gross Profit | $143M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $50.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 24% | XXX | XXX | XXX |
| EBIT | -$31.5M | XXX | $47.0M | XXX | XXX | XXX |
| EBIT Margin | -22% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | -$16.3M | XXX | $65.6M | XXX | XXX | XXX |
| Net Margin | -11% | XXX | 31% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Entrada Therapeutics's stock price is $8.
Entrada Therapeutics has current market cap of $288M, and EV of -$37.1M.
See Entrada Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$37.1M | $288M | XXX | XXX | XXX | XXX | $-0.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Entrada Therapeutics has market cap of $288M and EV of -$37.1M.
Entrada Therapeutics's trades at -0.2x EV/Revenue multiple, and -0.7x EV/EBITDA.
Equity research analysts estimate Entrada Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Entrada Therapeutics has a P/E ratio of -17.7x.
See valuation multiples for Entrada Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $288M | XXX | $288M | XXX | XXX | XXX |
| EV (current) | -$37.1M | XXX | -$37.1M | XXX | XXX | XXX |
| EV/Revenue | -0.3x | XXX | -0.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.7x | XXX | XXX | XXX |
| EV/EBIT | 1.2x | XXX | -0.8x | XXX | XXX | XXX |
| EV/Gross Profit | -0.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -17.7x | XXX | 4.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEntrada Therapeutics's last 12 month revenue growth is -74%
Entrada Therapeutics's revenue per employee in the last FY averaged $1.2M, while opex per employee averaged $0.9M for the same period.
Entrada Therapeutics's rule of 40 is -74% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Entrada Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Entrada Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -74% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -74% | XXX | -49% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 78% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Entrada Therapeutics acquired XXX companies to date.
Last acquisition by Entrada Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Entrada Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Entrada Therapeutics founded? | Entrada Therapeutics was founded in 2016. |
| Where is Entrada Therapeutics headquartered? | Entrada Therapeutics is headquartered in United States of America. |
| How many employees does Entrada Therapeutics have? | As of today, Entrada Therapeutics has 183 employees. |
| Who is the CEO of Entrada Therapeutics? | Entrada Therapeutics's CEO is Mr. Dipal Doshi. |
| Is Entrada Therapeutics publicy listed? | Yes, Entrada Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Entrada Therapeutics? | Entrada Therapeutics trades under TRDA ticker. |
| When did Entrada Therapeutics go public? | Entrada Therapeutics went public in 2021. |
| Who are competitors of Entrada Therapeutics? | Similar companies to Entrada Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Entrada Therapeutics? | Entrada Therapeutics's current market cap is $288M |
| What is the current revenue of Entrada Therapeutics? | Entrada Therapeutics's last 12 months revenue is $143M. |
| What is the current revenue growth of Entrada Therapeutics? | Entrada Therapeutics revenue growth (NTM/LTM) is -74%. |
| What is the current EV/Revenue multiple of Entrada Therapeutics? | Current revenue multiple of Entrada Therapeutics is -0.3x. |
| Is Entrada Therapeutics profitable? | Yes, Entrada Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
